Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are a structurally diverse group of similarly acting compounds that are widely prescribed and used for the management of pain associated with inflammatory conditions. Our present aim is to choose a leading drug for each class of NSAIDs, and to discuss the debated issues still pending about that drug, in order to weigh the risk/benefit ratio according to the current hypotheses on its mode of action. The leading compounds of the past and present which we have selected within this framework are aspirin, acetaminophen, celecoxib and rofecoxib. The discovery of nitric oxide (NO) in the last decade has resulted in proposing new NO-donors. Particularly interesting in this area has been the synthesis of NO-releasing anti-inflammatory drugs. The addition of NO to aspirin and to other NSAIDs has resulted in molecules that maintain their inhibitory effects on the cyclooxygenases (COX) but are devoid of cardiovascular, renal and gastrointestinal toxicity. The purpose of this review is also to update the “state-of-theart” of new classes of anti-inflammatory drugs such as COX-inhibiting nitric oxide donors (CINODs) and carbon monoxide (CO) releasing molecules (CO-RMs) as future tools in the therapy of inflammation and cellular proliferation.
Keywords: NSAIDS, aspirin, paracetamol, rofecoxib, NO-releasing NSAIDs, CINODs, CO-RMs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Evaluation of the Risk/Benefit Ratio of Old and New Anti-Inflammatory Drugs
Volume: 5 Issue: 4
Author(s): P. F. Mannaioni, V. Fabbroni, R. Mastroianni and E. Masini
Affiliation:
Keywords: NSAIDS, aspirin, paracetamol, rofecoxib, NO-releasing NSAIDs, CINODs, CO-RMs
Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) are a structurally diverse group of similarly acting compounds that are widely prescribed and used for the management of pain associated with inflammatory conditions. Our present aim is to choose a leading drug for each class of NSAIDs, and to discuss the debated issues still pending about that drug, in order to weigh the risk/benefit ratio according to the current hypotheses on its mode of action. The leading compounds of the past and present which we have selected within this framework are aspirin, acetaminophen, celecoxib and rofecoxib. The discovery of nitric oxide (NO) in the last decade has resulted in proposing new NO-donors. Particularly interesting in this area has been the synthesis of NO-releasing anti-inflammatory drugs. The addition of NO to aspirin and to other NSAIDs has resulted in molecules that maintain their inhibitory effects on the cyclooxygenases (COX) but are devoid of cardiovascular, renal and gastrointestinal toxicity. The purpose of this review is also to update the “state-of-theart” of new classes of anti-inflammatory drugs such as COX-inhibiting nitric oxide donors (CINODs) and carbon monoxide (CO) releasing molecules (CO-RMs) as future tools in the therapy of inflammation and cellular proliferation.
Export Options
About this article
Cite this article as:
Mannaioni F. P., Fabbroni V., Mastroianni R. and Masini E., Evaluation of the Risk/Benefit Ratio of Old and New Anti-Inflammatory Drugs, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2006; 5 (4) . https://dx.doi.org/10.2174/187152306778772865
DOI https://dx.doi.org/10.2174/187152306778772865 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of Mathematical Modelling for Improving the Tissue Engineering of Organs and Stem Cell Therapy
Current Stem Cell Research & Therapy State of Research Tracks and Property Protection of Photodynamic Sensitizers and Delivery Methodologies
Recent Patents on Chemical Engineering Paeonol Inhibits Migration, Invasion and Bone Adhesion of Small Cell Lung Cancer Cells
Current Signal Transduction Therapy Non-Analgesic Effects of Opioids: Opioid-induced Nausea and Vomiting: Mechanisms and Strategies for their Limitation
Current Pharmaceutical Design CD44-Targeting for Antitumor Drug Delivery: A New SN-38-Hyaluronan Bioconjugate for Locoregional Treatment of Peritoneal Carcinomatosis
Current Cancer Drug Targets PET/CT Based Dose Planning in Radiotherapy
Current Medical Imaging DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration
Current Cancer Drug Targets Evaluating Protein-protein Interaction (PPI) Networks for Diseases Pathway, Target Discovery, and Drug-design Using `In silico Pharmacology`
Current Protein & Peptide Science Defining the Cough Spectrum and Reviewing the Evidence for Treating Non-Specific Cough in Children
Current Pediatric Reviews Class II Phosphoinositide 3-Kinases as Potential Novel Drug Targets
Current Signal Transduction Therapy Lipid based Nanocarriers for Oral Delivery of Cancer Chemotherapeutics: An Insight in the Intestinal Lymphatic Transport
Drug Delivery Letters Main Anti-tumor Angiogenesis Agents Isolated From Chinese Herbal Medicines
Mini-Reviews in Medicinal Chemistry Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology NGR-based Strategies for Targeting Delivery of Chemotherapeutics to Tumor Vasculature
Anti-Cancer Agents in Medicinal Chemistry Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery Medicinal Chemistry and Anti-Inflammatory Activity of Nitric Oxide-Releasing NSAI Drugs
Mini-Reviews in Medicinal Chemistry Control of Protein Synthesis in Malignant Transformation - the Role of eIF4E and the eIF4E Binding Proteins in the Regulation of Apoptosis
Current Cancer Therapy Reviews Targeting Proteasomal Pathways by Dietary Curcumin for Cancer Prevention and Treatment
Current Medicinal Chemistry HOX Genes as Potential Markers of Circulating Tumour Cells
Current Molecular Medicine